These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11830536)

  • 1. The CLN3 gene is a novel molecular target for cancer drug discovery.
    Rylova SN; Amalfitano A; Persaud-Sawin DA; Guo WX; Chang J; Jansen PJ; Proia AD; Boustany RM
    Cancer Res; 2002 Feb; 62(3):801-8. PubMed ID: 11830536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide.
    Puranam KL; Guo WX; Qian WH; Nikbakht K; Boustany RM
    Mol Genet Metab; 1999 Apr; 66(4):294-308. PubMed ID: 10191118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
    Cianchi F; Papucci L; Schiavone N; Lulli M; Magnelli L; Vinci MC; Messerini L; Manera C; Ronconi E; Romagnani P; Donnini M; Perigli G; Trallori G; Tanganelli E; Capaccioli S; Masini E
    Clin Cancer Res; 2008 Dec; 14(23):7691-700. PubMed ID: 19047095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease.
    Narayan SB; Pastor JV; Mitchison HM; Bennett MJ
    Brain; 2004 Aug; 127(Pt 8):1748-54. PubMed ID: 15240430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
    Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
    Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.
    Chan CH; Ramirez-Montealegre D; Pearce DA
    Neuropathol Appl Neurobiol; 2009 Apr; 35(2):189-207. PubMed ID: 19284480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
    Lee CH; Liu M; Sie KL; Lee MS
    Anticancer Res; 1996; 16(4A):1805-11. PubMed ID: 8712704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.
    Elliott MJ; Stilwell A; Dong YB; Yang HL; Wong SL; Wrightson WR; Martin RC; McMasters KM
    Cancer Gene Ther; 2002 May; 9(5):453-63. PubMed ID: 11961668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective lysosomal arginine transport in juvenile Batten disease.
    Ramirez-Montealegre D; Pearce DA
    Hum Mol Genet; 2005 Dec; 14(23):3759-73. PubMed ID: 16251196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer.
    Liu X; Elojeimy S; El-Zawahry AM; Holman DH; Bielawska A; Bielawski J; Rubinchik S; Guo GW; Dong JY; Keane T; Hannun YA; Tavassoli M; Norris JS
    Mol Ther; 2006 Nov; 14(5):637-46. PubMed ID: 16887394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent.
    Chen T; Turner J; McCarthy S; Scaltriti M; Bettuzzi S; Yeatman TJ
    Cancer Res; 2004 Oct; 64(20):7412-9. PubMed ID: 15492264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of lysosomal acid phosphatase in CLN3-defective cells and mouse brain tissue.
    Pohl S; Mitchison HM; Kohlschütter A; van Diggelen O; Braulke T; Storch S
    J Neurochem; 2007 Dec; 103(6):2177-88. PubMed ID: 17868323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons.
    Dhar S; Bitting RL; Rylova SN; Jansen PJ; Lockhart E; Koeberl DD; Amalfitano A; Boustany RM
    Ann Neurol; 2002 Apr; 51(4):448-66. PubMed ID: 11921051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.
    Chattopadhyay S; Pearce DA
    Mol Genet Metab; 2000; 71(1-2):207-11. PubMed ID: 11001812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered gene expression in the eye of a mouse model for batten disease.
    Chattopadhyay S; Kingsley E; Serour A; Curran TM; Brooks AI; Pearce DA
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2893-905. PubMed ID: 15326100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemical localization of the Batten disease (CLN3) protein in retina.
    Katz ML; Gao CL; Prabhakaram M; Shibuya H; Liu PC; Johnson GS
    Invest Ophthalmol Vis Sci; 1997 Oct; 38(11):2375-86. PubMed ID: 9344361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.
    Spurgers KB; Coombes KR; Meyn RE; Gold DL; Logothetis CJ; Johnson TJ; McDonnell TJ
    Oncogene; 2004 Mar; 23(9):1712-23. PubMed ID: 14647426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.